Hematopathology cancer IHC panel

Hematopathology  assay
Deliver diagnostic confidence with the hematopathology panel

Hematological cancers vary significantly in both prognosis and aggressiveness, demonstrating a need for tools that assist pathologists in making confident diagnoses and helping to inform clinical decisions1,2,3. We offer over 65 cornerstone and novel hematopathology ready-to-use reagents, including key IHC antibodies and ISH probes, which aid in lymphoma diagnostics, leukemia diagnostics, myeloma diagnostics and other hematopoietic malignancies.

Our robust menu of tools aid in hematopathology diagnostics and treatment. Our portfolio of immunohistochemistry detection products delivers the high sensitivity and specificity you need from your assays. Our antibodies are ready-to-use on the fully-automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions.

Featured assays

CD20
CONFIRM anti-CD20 (L26) Primary Antibody

CONFIRM anti-CD20 (L26) Primary Antibody is a mouse monoclonal antibody (IgG2a, kappa) directed against an epitope present on human B lymphocytes. This antibody is intended for use to qualitatively identify cells of B lymphocytic lineage.

  • Mouse monoclonal antibody
  • OptiView DAB detection protocol now available
  • Aids in the qualitative identification of cells of B lymphocytic lineage
CD3
CONFIRM anti-CD3 (2GV6) Rabbit Monoclonal Primary Antibody

CONFIRM anti-CD3 (2GV6) is a rabbit monoclonal antibody (IgG) directed against the nonglycosylated epsilon chain of the human CD3 molecule. This antibody is intended for use to qualitatively identify T cells.

  • Rabbit monoclonal antibody
  • OptiView DAB detection protocol now available
  • Aids in the qualitative identification of T cells
bcl-2-SP66
bcl-2 (SP66) Rabbit Monoclonal Primary Antibody

bcl-2 (SP66) Rabbit Monoclonal Primary Antibody is directed against human bcl-2 expressed by B cells of the mantle zone and interfollicular T cells. This antibody exhibits a cytoplasmic staining pattern and may be used to aid in the identification of follicular lymphomas and diffuse large cell lymphomas

  • Rabbit monoclonal antibody
  • OptiView DAB detection protocol available
  • Targets a unique epitope for increased sensitivity
  • Aids in the identification of follicular lymphomas and diffuse large cell lymphomas
anti-CD30
anti-CD30 (Ber-H2) Mouse Monoclonal Primary Antibody

CD30 (Ber-H2) positive staining results may aid in the identification of classical Hodgkin lymphoma and anaplastic large cell lymphoma.

  • Mouse monoclonal antibody
  • OptiView DAB detection protocol available
  • Aids in the identification of classical Hodgkin lymphoma and anaplastic large cell lymphoma
c-MYC
c-MYC (Y69) Rabbit Monoclonal Primary Antibody

c-MYC (Y69) Rabbit Monoclonal Primary Antibody is directed against the transcription factor c-MYC, an important factor in cell cycle regulation. The anti-c-MYC (Y69) antibody exhibits a nuclear staining pattern and may be used to aid in the characterization of lymphoma.

  • Rabbit monoclonal antibody
  • OptiView DAB detection protocol available
  • Aids in the characterization of lymphoma
Cyclin-D1
VENTANA anti-Cyclin D1 (SP4-R) Rabbit Monoclonal Primary Antibody

VENTANA anti-Cyclin D1 (SP4-R) Rabbit Monoclonal Primary Antibody is directed against the Cyclin D1 molecule, a key cell cycle regulator, expressed primarily during the G1 phase of the cell cycle. This antibody exhibits a nuclear staining pattern, and may be used to aid in the identification of mantle cell lymphoma and breast carcinoma.

  • Rabbit monoclonal antibody
  • OptiView DAB detection protocol now available
Take an in-depth look at our full Hematopathology cancer IHC assay panel.

Search our product catalogs and documentation library in eLabDoc.

Roche Hematopathology cancer IHC panel in eLabDoc

  1. Tilly H, Gomes da Silva M, Violo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, Andre M, Johnson PW, Pfreudschuh M, Ladetto M. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Haematological Malignancies, Vol 26:S5, 2015.
  2. Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamo A, Zucca E. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Annals of Oncology, Vol 27:12, 2016.
  3. Zucca E, Arcaini L, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, Vol 31:1. 2020.